Partners

Alberta College of Pharmacy
Alberta Veterinary Medical Association
Alberta Dental Association and College
Alberta Health
Alberta Health Services
Alberta Medical Association
Alberta Pharmacists' Association
College and Association of Registered Nurses of Alberta
College of Physicians & Surgeons of Alberta
College of Podiatric Physicians of Alberta
Yukon Medical Council
The Triplicate Program was established in 1986 to monitor the use of certain medication prone to misuse and abuse for non-medical purposes.

The mandate of the TPP is:

To monitor prescribing, dispensing and utilization practices regarding targeted medications;

To improve patient care by providing relevant information and feedback on targeted drugs to prescribers and pharmacists;

To provide timely and relevant information on targeted medications to consumers, regulatory bodies and stakeholders;

To work with stakeholders to enable system level change that ensure appropriate use of targeted medications;

To ensure efficient and effective functioning of the TPP program.
TPP Alberta - 2017-18 Highlights

New TPP Secure Form
TPP Medication List
TPP Guide
2016 TPP Atlas
Data Utilization
TPP Alberta - 2017-18
Highlights

New TPP Secure Form

"TPP Alberta is about using data to optimize safe patient care."

Data Quality
Enhancements supporting TPP data quality capture

Collaboration
Added "Indications for Therapy" section

Security
Temperature sensitive ink and micro text feature
TPP Alberta - Resources

TPP Website
TPP Medication List
TPP Guide
2016 TPP Atlas

REDUCING PRESCRIPTION DRUG MISUSE AND ABUSE

Established in 1986, the Triplicate Prescription program (TPP) monitors the use of certain drugs prone to misuse and abuse in Alberta. TPP is administered by CPSA in collaboration with partner organizations.

TPP collects prescribing and dispensing data for listed drugs.

When the data meet certain criteria, physicians and others involved in the care of the patient are alerted, provided with information and directed to resources that can support them in providing safe care.

TPP Medications List
For a listing of Type 1 & Type 2 medications
2016 TPP Atlas - Analysis

Figure 5. Benzodiazepine Patients by Age Group, 2016

Table 4. Opioid Prescriptions, Patients, Prescribers and Pharmacies by Main Ingredient, 2016
## Table 5. Opioid Patients and Associated Prescribers by Dose, 2013-2016

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>≥ 90 OME/day</td>
<td>13,670</td>
<td>2.5</td>
<td>14,249</td>
<td>2.5</td>
<td>14,498</td>
<td>2.6</td>
<td>14,638</td>
<td>2.5</td>
</tr>
<tr>
<td>≥ 100 OME/day</td>
<td>12,487</td>
<td>2.3</td>
<td>13,012</td>
<td>2.3</td>
<td>13,206</td>
<td>2.3</td>
<td>13,284</td>
<td>2.3</td>
</tr>
<tr>
<td>≥ 200 OME/day</td>
<td>6,457</td>
<td>1.2</td>
<td>6,606</td>
<td>1.2</td>
<td>6,631</td>
<td>1.2</td>
<td>6,485</td>
<td>1.1</td>
</tr>
<tr>
<td>≥ 400 OME/day</td>
<td>2,590</td>
<td>0.5</td>
<td>2,580</td>
<td>0.5</td>
<td>2,529</td>
<td>0.4</td>
<td>2,370</td>
<td>0.4</td>
</tr>
<tr>
<td>≥ 600 OME/day</td>
<td>1,274</td>
<td>0.2</td>
<td>1,269</td>
<td>0.2</td>
<td>1,228</td>
<td>0.2</td>
<td>1,138</td>
<td>0.2</td>
</tr>
<tr>
<td>≥ 1,000 OME/day</td>
<td>470</td>
<td>0.1</td>
<td>488</td>
<td>0.1</td>
<td>430</td>
<td>0.1</td>
<td>371</td>
<td>0.1</td>
</tr>
<tr>
<td>≥ 2,000 OME/day</td>
<td>84</td>
<td>0.0</td>
<td>74</td>
<td>0.0</td>
<td>67</td>
<td>0.0</td>
<td>48</td>
<td>0.0</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td>547,910</td>
<td></td>
<td>559,668</td>
<td></td>
<td>563,565</td>
<td></td>
<td>576,485</td>
<td></td>
</tr>
</tbody>
</table>

## Table 14. Benzodiazepine Patients and Associated Prescribers by Number of Ingredients, 2013-2016

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>2+</td>
<td>70,382</td>
<td>70.5</td>
<td>14,803</td>
<td>20.9</td>
<td>77,846</td>
<td>20.8</td>
<td>88,134</td>
<td>20.7</td>
</tr>
<tr>
<td>3+</td>
<td>12,568</td>
<td>4.0</td>
<td>14,159</td>
<td>4.0</td>
<td>14,518</td>
<td>3.9</td>
<td>15,015</td>
<td>2.9</td>
</tr>
<tr>
<td>4+</td>
<td>2,066</td>
<td>0.8</td>
<td>2,988</td>
<td>0.8</td>
<td>2,772</td>
<td>0.7</td>
<td>2,844</td>
<td>0.7</td>
</tr>
<tr>
<td>5+</td>
<td>564</td>
<td>0.3</td>
<td>590</td>
<td>0.3</td>
<td>500</td>
<td>0.1</td>
<td>502</td>
<td>0.1</td>
</tr>
<tr>
<td>6+</td>
<td>109</td>
<td>0.0</td>
<td>114</td>
<td>0.0</td>
<td>116</td>
<td>0.0</td>
<td>118</td>
<td>0.0</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td>341,318</td>
<td></td>
<td>357,005</td>
<td></td>
<td>373,852</td>
<td></td>
<td>386,416</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>2+</td>
<td>8,235</td>
<td>76.3</td>
<td>8,056</td>
<td>76.0</td>
<td>6,253</td>
<td>77.8</td>
<td>6,068</td>
<td>77.7</td>
</tr>
<tr>
<td>3+</td>
<td>5,521</td>
<td>51.3</td>
<td>5,032</td>
<td>52.2</td>
<td>4,163</td>
<td>51.6</td>
<td>4,171</td>
<td>51.6</td>
</tr>
<tr>
<td>4+</td>
<td>2,012</td>
<td>27.8</td>
<td>2,068</td>
<td>28.2</td>
<td>2,230</td>
<td>26.9</td>
<td>2,430</td>
<td>26.9</td>
</tr>
<tr>
<td>5+</td>
<td>1,292</td>
<td>12.0</td>
<td>1,166</td>
<td>12.8</td>
<td>1,223</td>
<td>11.1</td>
<td>1,430</td>
<td>11.1</td>
</tr>
<tr>
<td>6+</td>
<td>448</td>
<td>4.3</td>
<td>500</td>
<td>4.4</td>
<td>407</td>
<td>4.1</td>
<td>472</td>
<td>3.8</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td>10,754</td>
<td></td>
<td>11,251</td>
<td></td>
<td>12,019</td>
<td></td>
<td>12,738</td>
<td></td>
</tr>
</tbody>
</table>

* can include prescriptions from multiple prescribers
**TPP Alberta - 2017-18 Data Utilization**

**MD Snapshot Report**

Personalized reports based on TPP data sent to over 8,000 physicians prescribing opioids or benzodiazepines focusing on evidence-informed thresholds

**High Risk Alert Letters**

Over 1000 alert letters were sent to prescribers based on thresholds related to high OME, seeing multiple providers and multiple pharmacies in a three month period

**Mentorship & Education**

Daily Oral Morphine Equivalent (DOME) Program identified prescribers who had patients with very high OME values and paired them with an educational mentor

---

**Three Month Prescribing Snapshot: Opioids (1)**

<table>
<thead>
<tr>
<th>Year Practice</th>
<th>Comparator Group</th>
<th>Median (2)</th>
<th>Percentile</th>
</tr>
</thead>
<tbody>
<tr>
<td>Patient(s) to whom you prescribed opioids</td>
<td>18</td>
<td>34</td>
<td>47.1</td>
</tr>
<tr>
<td>Total OME/day prescribed (3)</td>
<td>375</td>
<td>367.4</td>
<td>99.9</td>
</tr>
<tr>
<td>Average OME/disp/patient (4)</td>
<td>21</td>
<td>11.4</td>
<td>64.1</td>
</tr>
<tr>
<td>Opioid naive patient(s) receiving a long-acting opioid prescribed by you (5)</td>
<td>0</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Patient(s) receiving one or more opioid and one or more BZD prescribed by you</td>
<td>5</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Patient(s) receiving opioids at an average dose &gt;100 OME/day (6)</td>
<td>7</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
TPP Alberta - 2017-18
OME DDD Rates/1000

FROM Q4 2016 (FIRST MD SNAPSHOT MAIL OUT) TO Q1 2018

OME/Day/1000 Population

19%

DDD/Day/1000 Population

14%

MD Snapshot
Inaugural Mail Out
to 8,213 physicians
TPP Alberta - Member Prescribing

Benzo Prescribers 2017

Physicians (72.84%)  Dentists (0.64%)  Veterinarians (3.63%)  Nurse Practitioners (1.84%)
Pharmacists (21.06%)

Benzo Prescriptions 2017

Physicians (97.59%)  Dentists (0.02%)  Veterinarians (0.16%)  Nurse Practitioners (0.32%)
Pharmacists (1.91%)
# TPP Grant Report 2017-18

## Financial Summary

<table>
<thead>
<tr>
<th>Current Fiscal Period: (Year 1)</th>
<th>Full Term of Agreement: (Year 1)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Year-To-Date</td>
<td>Agreement-To-Date</td>
</tr>
<tr>
<td>Budget</td>
<td>Actuals</td>
</tr>
<tr>
<td>Variance</td>
<td>Budget</td>
</tr>
<tr>
<td>Actuals</td>
<td>Variance</td>
</tr>
</tbody>
</table>

### Revenue
- Contribution from Alberta Health & Wellness (Surplus): 23,793.56, 23,793.56, -
- Contribution from Alberta Health & Wellness: 636,206.44, 536,206.44, (100,000.00)
- Government Grant - Investment Income: 1,088.20, 1,088.20, 1,088.20
- Grant - Other Sources: 127,000.00, 127,000.00, 1,625.00, 127,000.00, 127,000.00, 1,625.00
- CPSA Contribution: 151,000.00, 151,000.00, 950.00, 151,000.00, 151,000.00, 950.00
- **Total Revenue:** 938,000.00, 848,255.99, (89,749.10)

### Expense
- **General Program Expenditures**
  - Consulting: 166,400.00, 163,209.39, (3,190.61)
  - Legal: 3,000.00, (3,000.00)
  - Occupancy Costs: 50,600.00, 49,125.01, (1,474.99)
  - Operating Costs: 63,200.00, 60,650.01, (2,549.99)
  - Printing, Supplies & Courier: 21,700.00, 17,632.68, (4,067.32)
  - Special printing: 325,500.00, 302,269.87, (23,230.13)
  - **Sub-total:** 630,400.00, 592,886.94, (37,513.06)

- **Staffing Costs**
  - Salaries & Benefits: 304,400.00, 254,532.59, (49,867.41)
  - Professional Development: 3,200.00, 740.24, (2,459.76)
  - **Sub-total:** 307,600.00, 255,272.83, (52,327.17)

- **Committee Expenses**
  - Travel, Meals & Accommodation, Sundry: - 91.13, 91.13
  - **Sub-total:** - 91.13, 91.13

- **Prior Period Adjustment**
  - Salaries & Benefits: -
  - **Sub-total:** -

- **Total Expenses:** 938,000.00, 848,255.99, (89,749.10)

### Surplus < Deficit >
- (6,587.70), (6,587.70)

### Unexpended Funding
- Opening Balance: Prior Year's Cumulative Unexpended Retention -
- Add (Subtract) Current Surplus/Deficit: (6,587.70)
- **Retained Unexpended Funding**
  - Form: (FINAL YEAR ONLY): Less: Approved Request(s) for Retention of Unexpended Funding (FINAL YEAR ONLY)
  - Closing Balance: «additional installment payment to be received for Year 1»
  - (6,587.70)

### Finance Contact:
- Tracy Simons: 780-969-4983
- EJ Leas: (780) 969-4946

### Finance Approval:
- Director, Operations: 780-563-5983
- **Signature**

S:\Tools\Accounting Tool\Govt\TPP\Grant\2017-2018 AH&W TPP\1st Year April 2017 to March 2018 TPPT AH&W Financials Mar31.2018.xls
Mar 31 2018